Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC lifted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,149.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,984 shares of the company's stock after buying an additional 21,145 shares during the period. Tower Research Capital LLC TRC owned about 0.06% of Keros Therapeutics worth $364,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. AlphaQuest LLC increased its position in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after buying an additional 2,964 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics in the 4th quarter valued at about $90,000. Exchange Traded Concepts LLC purchased a new position in Keros Therapeutics in the 4th quarter valued at about $99,000. CANADA LIFE ASSURANCE Co boosted its stake in shares of Keros Therapeutics by 207.8% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock worth $116,000 after purchasing an additional 4,976 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after buying an additional 1,372 shares in the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Price Performance

KROS traded up $0.07 during trading hours on Wednesday, reaching $13.83. 153,268 shares of the stock traded hands, compared to its average volume of 811,510. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The company has a market cap of $561.65 million, a price-to-earnings ratio of -2.65 and a beta of 1.32. The firm's fifty day simple moving average is $12.05 and its two-hundred day simple moving average is $25.42.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. The business had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same period in the previous year, the company earned ($1.21) earnings per share. On average, research analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on KROS. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Wells Fargo & Company reduced their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. Truist Financial lowered their price target on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Scotiabank cut their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating on the stock in a report on Thursday, January 16th. Finally, Piper Sandler dropped their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, Keros Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $40.33.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 22.90% of the stock is currently owned by corporate insiders.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.